Jocasta Neuroscience
Private Company
Funding information not available
Overview
Jocasta Neuroscience is a private, pre-clinical biotech focused on harnessing the therapeutic potential of the Klotho protein for cognitive health. The company's approach is genetically validated, building on human genetic data showing that individuals with naturally higher Klotho levels exhibit better cognitive function and reduced risk of neurodegenerative diseases. Jocasta has raised a $35M Series A to advance its lead candidate, JN-0413, a subcutaneous formulation, with human trials estimated to begin in 2026. The company is led by a team of experts in cognitive health and longevity.
Technology Platform
Platform focused on the therapeutic potential of the Klotho protein, leveraging human genetic validation (KL-VS variant) and preclinical proof-of-concept in primates and mice to develop synthetic Klotho protein therapies for cognitive enhancement and neuroprotection.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Jocasta is a pioneer in developing an exogenous Klotho protein therapy, placing it in a potentially first-in-class position. Competition exists from companies targeting neurodegenerative diseases (e.g., amyloid, tau) and the broader longevity sector, but direct competitors with a Klotho-based therapeutic are not yet prominent. Its main competition may come from future alternative approaches to modulate the Klotho pathway.